Relevant funding bodies in 28 European Union (EU) countries were identified by a multistep process involving experts in each country. Projects above a funding threshold of 100 ke during the period 2010-2012 were included using a standard questionnaire. Results were classified by experts and an adaptive text analysis software to a CVresearch taxonomy, integrating existing schemes from ESC journals and congresses. An on-line query portal was set up to allow different users to interrogate the database according to their specific viewpoints. 
Introduction
Cardiovascular diseases (CVD) are the no. 1 killer in Europe, causing the death of over 4 million people per year in the WHO European Region and 1.9 million in the EU. CVD is also estimated to cost the EU economy e196 billion every year. A significant increase in CVD prevalence is expected over the next 20 years based on current trends. 1 Therefore, new approaches to screening and prevention, early detection and management, new and innovative treatments and effective and cost effective service delivery to tackle CVD are essential.
CardioScape-a survey of the European cardiovascular research landscape in order to inform future transnational and national research strategies-is a 23-month project funded by the European Union FP7 research programme. Co-ordinated by the European Society of Cardiology (ESC), together with PNO-an independent innovation grants consultancy-the project outlined the current CVD research and innovation landscape across Europe. These data on CVD research funding, generously provided by European and national funding bodies in the public and private sectors, will allow experts from academia, the funding bodies themselves, political decision makers and industry to establish the extent of duplication across national research programmes, identify gaps that reduce opportunities for innovation, highlight areas where coordination can be improved and to define future funding priorities and strategies for CVD research in Europe.
This report outlines the funded CVD research activities based on data collected over the time period 2010-2012 (3 years) and presents an overview of this scientific landscape. The Cardioscape database is a publicly available resource for the whole scientific community. Funding bodies and investigators are invited to continue populating this database with research projects funded from 2012 onwards to make it a living repository of cardiovascular research.
Methods

Data collection
The data collection on the cardiovascular research projects was carried out in a 16-month period and both European and national level projects were covered. The survey questionnaire was designed in collaboration with the CardioScape Scientific Committee and other relevant stakeholders and a pilot phase was launched in order to test the data collection process, which included Belgium, the Netherlands, Slovenia and Spain. Following the success of the pilot study, the questionnaire was then rolled out to all EU-28 Member States.
In order to maximize the response rate and the reliability of the data, a multi-step process was developed: The CardioScape project manager contacted first the Presidents of the EU28 National Cardiac Societies, which are members of the ESC, to identify three leading experts in CVD research in their country, one for each of the following areas: basic, clinical, and epidemiological science. These experts were then invited to provide a list of CVD research funding organizations in their area of expertise which were then contacted by the project manager. Last, the identified funding organizations were invited to fill in an online questionnaire.
Only projects meeting the following criteria qualified for the database:
• Grant awards > _e100 000 or equivalent in other currencies • Projects commencing in one of the following years: 2010, 2011, and 2012
• Funding for researchers or research groups, i.e. no institutional funding.
The rationale for the lower funding limit was to evaluate only funding projects which are in a range to include the hiring of staff. In future studies, the fully automatic evaluation irrespective of the number of projects as established in the CardioScape project, will allow to include all funding ranges. The CardioScape secretariat was responsible for the systematic follow up of the data collection process, which involved letters, emails and telephone reminders towards the actors involved in the process, including the Presidents of National Cardiac Societies and their nominated research experts, as well as Steering and Scientific Committee members. An active data collection process proved to be mandatory to obtain a reasonably comprehensive data set.
Collected research and funding data include:
• 157 organisations from all EU-28 Member States were contacted of which 130 organisations responded to the questionnaire. From the 130 responding agencies, 52% provided a complete response, 3% provided incomplete information (e.g. missing abstract, no budget indication by project), 13% awarded no grant > _e100.000 and 22% awarded no grant for CVD research in observed time period, 10% refused to provide any information. In total, 2476 individual research projects were included in the CardioScape analysis and database. While we gather from the response rate that the used approach provides a comprehensive picture of the funding landscape it is not possible to provide an exact figure for percentage coverage due to the absence of independent data.
Taxonomy
Research projects were initially assigned to one of three research domains: (i) population, (ii) basic science or (iii) clinical/human. Projects were excluded if they did not investigate cardiovascular disease. Projects were classified using a common vocabulary and hierarchy of terms. A detailed taxonomy was compiled by integrating the topic list and keywords from ESC congress abstracts and the six ESC specialty journals. A hierarchy of terms was created with major topics and sub-topics defined. The final vocabulary contained 62 major topics and 559 subtopics. Generic keywords like prognosis, management, epidemiology and pathophysiology were not included.
Classification
The first 100 projects were classified manually by consensus opinion of three cardiologists and investigators (CC, FO, AT). The next 100 projects were classified independently with any inconsistencies in classification reviewed by the Scientific Committee. Manual classification of projects according to research areas and topics using the developed taxonomy proved to be extremely time consuming and resulted in inconsistencies in classifications.
Therefore, an automatic analysis using rule-based text mining and enabling addition of synonyms to the hierarchy of terms was established in collaboration with the Structural Bioinformatics Group, Charité Medical School, Berlin. The algorithm did use the title and abstract (if available) to extract topics and subtopics. To define the relevance of identified terms, a scoring algorithm was implemented depending on position in the text and distance between relevant terms, frequency and co-occurrence of taxonomy and disease-based keywords. The accuracy of the automatic classification was progressively improved with the use of further synonyms and guided by simultaneous manual classification until a very high concordance (>85%) between automatic and manual classifications was reached.
User interface
A website was designed allowing one to query the database from varying viewpoints including those of individual researchers, funding agencies and policy makers. It provides exports of the data for subsequent expert review and analysis. The CardioScape website 2 developed by the ESC Web Department, hosts the database, which is publicly available. The database is currently maintained by the ESC and will be updated and enhanced by the CardioScape II team, starting in late 2016.
The website provides information on project objectives, methods, the investigators and relevant contact details related to CVD research related projects funded in Europe. It allows different types of queries including search fields for country, research area (basic/preclinical research, human/ clinical research and epidemiology/population/prevention research), research topic, funding agency (including classifying funding agencies as either public/governmental or private/charitable), year and funding amount. All search fields can be combined for an advanced search using logical connections (AND, OR and NOT). For a given search, the total number of projects and the individual projects are displayed. Upon availability, the CardioScape website also provides information on the project's objectives, structure, involved parties and relevant news and contact details. The collection of the names of the principal investigators was not within the scope of this project but should be included in the future.
Results
For the present report, the data on funding of CVD research projects in Europe were analysed according to various aspects. Geographical distribution of funding was analysed by comparing EU-funding to national funding and by comparing national funding among the EU-28 member states according to population size, economic strength or CVD mortality load. The necessary additional data were obtained from publications of Eurostat, the statistical office of the European Union. size. However, there are strong deviations from a strict proportionality (middle panel). Four countries stand out with spending between 4 and 8 eper capita, namely the United Kingdom, Ireland, Sweden, and The Netherlands. This may in part be related to the power of private/charity organisations and fund raising culture. A very similar picture is seen in the lower panel which shows CVD research funding in percent of GDP (national gross domestic product) questioning the hypothesis that this effect is purely dues to differences in wealth. All funding figures are based on the projects included in the CardioScape database. This is further analysed in Figure 2 . For most countries there seems to be a positive correlation between GDP and cardiovascular funding. However, this correlation becomes significant (R 2 = 0.45 and P = 0.002) only after eliminating the above mentioned four top runners with higher than expected spending and Luxemburg with extreme GDP per capita from the analysis. For the remaining group, about 1eper capita and year is spent on cardiovascular projects (registered by CardioScape) per 100.000 eGDP. Another relevant aspect is the relation between CVD research spending and CVD related mortality. Such correlations could be interpreted in two ways exchanging cause and effect: a high CVD-related mortality could be an incentive to spend more on CVD research, or else strong research efforts could lead to a decrease of CVD related mortality. Figure 3 , comparing per capita spending with CVD related mortality, rather seems to support the second assumption. Eastern and Central European countries, where CVD causes up to 50% of deaths have little research dedicated to CVD according to this analysis. On the contrary, CVD mortality has significantly fallen over the last decades in North and Western Europe where project funding dedicated to CVD research is high. However, the countries with the lowest mortality (France, Spain) are not those with the highest funding and in the group of countries with the second lowest mortality score, very different funding levels prevail. This is supported by a statistical analysis which shows that only about 11% of the differences in CVD research are explained by CVD related mortality (linear correlation, R 2 = 0.11 and P = 0.09). Thus additional factors of high relevance, possibly including life style differences, must be present. The question to which extent different research areas are supported is assessed in Figure 4 . There is a general trend with most spending assigned to human/clinical research followed by basic/preclinical and epidemiological/prevention/public health research trailing behind. The respective distribution varies strongly among countries. It is notable that in some countries like Ireland, Germany, or Italy the proportion of spending for clinical research is particularly high, while in Finland or Sweden more that 50% of spending is assigned to basic research and some countries such as France or Germany spend very little on epidemiological research. It should be noted that the data for smaller countries with only few research projects awarded (e.g. Croatia n = 1, Cyprus n = 4) are not representative.
CVD research funding distribution in Europe
As shown in Figure 5 , also the distribution of funding sources within European countries is rather heterogeneous among countries. Although the by far the largest single funding organization with more than 257m espent is the EU, national governmental funding dominates in many countries such as Ireland, Belgium, Finland, Poland, or Portugal. The top 5 national governmental funding organizations were Deutsche Forschungsgemeinschaft (80m e, Germany), Medical Research Council (51m e, United Kingdom), Deutsches Zentrum für Luft-und Raumfahrt (43m e, Germany), Agence National de la Recherche (23m e, France), and National Institute for Health Research (16m e, United Kingdom). In some countries EU funds provided 50% or more of total funding, namely in Italy, Spain, and Germany. Of interest is the high proportion of funding by nongovernmental organizations (NGO) in some countries. The NGO funding share is greatest in Greece, followed by the United Kingdom, The Netherlands, and Austria. The two largest NGOs are located in the United Kingdom (British Heart Foundation, 120m e; Wellcome Trust, 104m e) and each of these provided more funding then the largest governmental organization in Europe. Three quarters of the 
Distribution of funding to research areas and topics
A detailed analysis of the funding distribution among the 62 major topics and 559 sub-topics for all included countries can be performed using the online CardioScape database (see Supplementary material online, Figure 1 ). Atherosclerosis research received the highest funding (9.7%) followed by epidemiology/study design (8.7%), prevention (6.8%), and cardiovascular pathology (6.5%). Within 'atherosclerosis', inflammation research is represented with 27% followed by cytokines (15%), lipids (14%), and oxidative stress (14%).
Discussion
Research aspects: funding deficiencies and suggestions
The information obtained by the CardioScape project can be viewed from very different perspectives including those of individual researchers, funding agencies and political decision makers. The majority of such questions, e.g. related to individual research projects and topics can be best addressed using the online CardioScape database. In the context of the present publication only a few exemplary observations, focusing on funding deficiencies and future options for different research areas shall be addressed as interpreted by the authors.
Ageing/Gender-Despite the imminent and intensively discussed changes in demography, only 20 projects in the CardioScape database concern the prevention, causes, occurrence and treatment of cardiovascular disease in the elderly and their association with the ageing process. It is of note that the Horizon 2020 call does not include a disease pre-specification in this area, a further evidence that ageing deserves stronger consideration in funding strategy. Similar arguments hold for gender aspects in cardiovascular research projects. CARDIOVASCULAR NURSING-Funding is restricted to the national level and relatively small projects. No projects address nursing education neither in human/clinic nor in epidemiology/prevention research areas. Thus, an increased support for research in cardiovascular nursing is needed. E-CARDIOLOGY-While a sizeable number of projects in this area was funded (150), related approaches have not entered the 0 mainstream 0 of cardiovascular science or practice. To use the full potential of digitization for cardiovascular medicine, supranational funding to corroborate the strength, interaction and visibility of the field by supporting conferences, career options and translational efforts would be needed. Heart Failure-HF is a clinical area with lot of studies in the database (212), but just a minority of them are focused on the most relevant unmet needs: one study specifically focused on chronic HF with preserved ejection fraction and five studies on acute HF. Platelet function-In this area research funding is limited to only seven EU countries. There is also very limited publicly funded clinically based research on healthy volunteers or patients exploring newer modes of platelet function testing or the use of new anti platelet treatment strategies. One may assume that this is partly due to great amount of funding by industry. Prevention-The number of projects funded and resources allocated specifically to research on primary prevention in Europe is scarce (16 projects) despite the fact that industry funding is generally not directed to this area. There is an urgent need for new population-based observational cohort studies in order to develop more accurate and up to date models to estimate the total CV risk in an apparently healthy population; community-based intervention trials regarding the efficacy and safety of lifestyle-and environmentrelated exposures are needed to develop evidence-based health policies in the field of preventive cardiology. Research by networks of epidemiologists and public health workers with special interest in CVD on the implications of the changing CV mortality pattern and the changing time course of CVD is needed and requires increased funding. Regenerative Medicine/Stem Cells-Despite substantial activity in this area (>200 projects) some aspects in this field have not been adequately addressed including: (i) Stem cells (iPS) as models for cardiac development. (ii) Tissue engineering for myocardial regeneration. (iii) Cell cycle activation strategies of myocytes or transdifferentiation strategies of non-myocytes. Stemi-Nine projects on 'STsegment-elevation acute coronary syndrome' (total funding of >2 700 000 EUR) are included in the database, with most of the funding addressing ischaemia/reperfusion injury. However, none of these studies has resulted in a guidelines recommended treatment suggesting that international collaboration and new research strategies might be required. 
Supplementary material
Supplementary material is available at European Heart Journal online.
